valve

Claudicación Intermitente: ¿el tratamiento invasivo es superior al tratamiento farmacológico?

Long-Term Mortality in Non-Obstructive Lesions in the Left Main Coronary Artery

Left main coronary artery (LMCA) intervention with significant lesions on both coronary angiography and intravascular ultrasound (IVUS), either through angioplasty (PCI) or myocardial revascularization surgery (MRS), is directly related to a decrease in long-term adverse clinical events. However, the relationship between subclinical LMCA disease (preserved luminal diameters) and long-term mortality is still unknown. A retrospective<a href="https://solaci.org/en/2022/11/24/long-term-mortality-in-non-obstructive-lesions-in-the-left-main-coronary-artery/" title="Read more" >...</a>

See the Presentations of the 12th ProEducar Fellows Course

During SOLACI-SOCIME 2022, our traditional education program for young interventionists ProEducar Fellows Course was held.&nbsp; Discover the presentations of the prestigious interventionists that made part of this 12th edition here below.&nbsp; Dr. Leandro Lasave (ARG) &nbsp;Transradial access: When and how? Practical lesson for access without complications PRESENTATION Dr. Alejandro Alcocer (MEX) &nbsp;Practical demonstration of aortic<a href="https://solaci.org/en/2022/11/21/see-the-presentations-of-the-12th-proeducar-fellows-course/" title="Read more" >...</a>

Inflamación crónica, enfermedad coronaria y cáncer: distintas caras de una misma moneda

We Should Start Considering Pulmonary Hypertension After TAVR

Pulmonary hypertension is associated with higher mortality after both aortic valve replacement and transcatheter aortic valve replacement (TAVR). This is a dynamic phenomenon, and what happens after TAVR during the periprocedure and its impact are yet to be evaluated. Researchers conducted a subanalysis of the Japanese OCEAN TAVI Registry, which included 1872&nbsp;patients who were divided<a href="https://solaci.org/en/2022/10/25/we-should-start-considering-pulmonary-hypertension-after-tavr/" title="Read more" >...</a>

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

Patients with INOCA in the ISCHEMIA Trial

There has been an increase in the diagnosis of patients with proven ischemia who did not present obstructive coronary lesions (defined as the absence of stenosis 50%), called ischemia with non-obstructive coronary arteries (INOCA). These patients are at a higher risk for major adverse cardiac events (MACE) compared with the rest of the population. The<a href="https://solaci.org/en/2022/10/18/patients-with-inoca-in-the-ischemia-trial/" title="Read more" >...</a>

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

SURTAVI at 5 Years

Transcatheter aortic valve replacement (TAVR) by transfemoral access has shown great benefit for different risk groups, but its long-term durability is still uncertain. Available evidence comes from small analysis and a single randomized trial with 280&nbsp;patients and an 8&nbsp;year follow-up: the NOTION Trial, where TAVR showed less valvular degeneration than aortic valve replacement (AVR) surgery.<a href="https://solaci.org/en/2022/10/17/surtavi-at-5-years/" title="Read more" >...</a>

A Simple Score for Mortality and Cardiac Failure after Edge-to-Edge with MitraClip

Mitral regurgitation (MR) is the most frequent type of valve heart disease, and the COAPT has shown that edge-to-edge with guideline directed medical treatment (GDMT) at maximal tolerated dose (MTD) is superior to medical treatment alone.&nbsp; However, we did not have a score to predict patient evolution when treated with this strategy. Researchers analyzed the<a href="https://solaci.org/en/2022/10/14/a-simple-score-for-mortality-and-cardiac-failure-after-edge-to-edge-with-mitraclip/" title="Read more" >...</a>

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

Prognostic Impact of Acute Kidney Injury Following Tricuspid Transcatheter Edge-to-Edge Repair

Tricuspid failure (TF) mostly affects the elderly and, because of this, is associated with comorbidities that increase surgical risk.&nbsp; Tricuspid edge to edge repair (TEER) has surged as a valid alternative for the mitral valve in high-risk patients and, at present, is increasingly being used for tricuspids.&nbsp; One of the complications following TEER is acute<a href="https://solaci.org/en/2022/10/12/prognostic-impact-of-acute-kidney-injury-following-tricuspid-transcatheter-edge-to-edge-repair/" title="Read more" >...</a>

La enfermedad vascular periférica se asocia a más eventos en el TAVI

Is Right Ventricle-Pulmonary Artery (RV-PA) Coupling Important in Low Risk TAVR?

TAVR has long been an effective strategy to treat aortic stenosis. However, ventricular damage starts further before symptom onset, also affecting the left ventricle, pulmonary vessels, the right ventricle, the tricuspid valve, and the right atrium.&nbsp; It increases arterial afterload and uncouples the right ventricle and the pulmonary artery, defined by transthoracic&nbsp;echocardiogram as the relationship<a href="https://solaci.org/en/2022/09/30/is-right-ventricle-pulmonary-artery-rv-pa-coupling-important-in-low-risk-tavr/" title="Read more" >...</a>

Jornadas PAraguay 2022 | Reviva el Concurso de Jóvenes Cardiólogos Intervencionistas

Paraguay Sessions 2022 | Relive the Contest for Young Interventionists

Relive the traditional Contest for Young Interventional Cardiologists at Paraguay Regional Sessions 2022. During this scientific session, carried out on June 30, 2022, 8 challenging interventional cardiology clinical studies were presented by promising young interventionists from Latin America. They were assessed by a panel of experts that also commented on the most relevant points of<a href="https://solaci.org/en/2022/09/26/paraguay-sessions-2022-relive-the-contest-for-young-interventionists/" title="Read more" >...</a>

TCT 2022

TCT 2022 | PROTECTED TAVR

Stroke is still a major complication of transcatheter aortic valve replacement (TAVR), with a 30-day mortality of 16.7%. Even in the absence of symptoms, most patients (68-93%) have some type of diffusion imaging defect after TAVR implantation. The Sentinel cerebral protection device (CPD) (Boston Scientific) received FDA approval for the capture of emboligenic material that<a href="https://solaci.org/en/2022/09/21/tct-2022-protected-tavr-3/" title="Read more" >...</a>

Top